A.R.T. Advisors’s Travere Therapeutics TVTX Stock Holding History

A.R.T. Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-72,474	Closed	-$1.03M	–	933
2019 Q4	$1.03M	Sell	72,474 -10,700	-13%	-$137K	0.05%	548
2019 Q3	$964K	Buy	83,174 +55,300	+198%	+$914K	0.05%	571
2019 Q2	$560K	Buy	27,874 +1,100	+4%	+$21.7K	0.03%	707
2019 Q1	$606K	Buy	26,774 +4,600	+21%	+$102K	0.04%	675
2018 Q4	$502K	Buy	+22,174	New	+$552K	0.03%	729
2018 Q2	–	Sell	-44,870	Closed	-$1M	–	1758
2018 Q1	$1M	Buy	+44,870	New	+$1.07M	0.04%	665

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

A.R.T. Advisors's TVTX Position: Q1 2020 in Review

A.R.T. Advisors sold out of Travere Therapeutics (TVTX) in Q1 2020, closing a stake of 72,474 shares — an estimated $1.03M sold.

A.R.T. Advisors first reported a position in TVTX in Q1 2018 and held it in 6 quarters. The position peaked at $1.03M in Q4 2019. 124 funds tracked by Wall St. Rank hold TVTX as of Q1 2020.

A.R.T. Advisors reported no remaining Travere Therapeutics position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 72,474 Travere Therapeutics shares in Q1 2020, an estimated $1.03M.
A.R.T. Advisors first reported a position in Travere Therapeutics in Q1 2018 and held it in 6 quarters.
A.R.T. Advisors's Travere Therapeutics position peaked at $1.03M in Q4 2019.
124 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.